NCT03547115 2026-03-17A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AMLMEI Pharma, Inc.Phase 1 Terminated84 enrolled
NCT03740529 2026-01-27A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLEli Lilly and CompanyPhase 1/2 Completed803 enrolled 2 FDA
NCT05107856 2024-01-31PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesPrelude TherapeuticsPhase 1 Terminated21 enrolled
NCT03357627 2023-02-08A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaCalithera Biosciences, IncPhase 1 Completed43 enrolled
NCT03135262 2021-12-07A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)Hoffmann-La RochePhase 1/2 Terminated29 enrolled 18 charts
NCT02187861 2019-06-05A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)Hoffmann-La RochePhase 2 Completed163 enrolled 30 charts